The Rebound Study
This Study is a prospective pivotal clinical study to assess the safety and effectiveness of the ALPFA GRAIL PFA System in the treatment of men over the age of 45 with lower urinary tract symptoms associated with BPH.
A New Option
The ALPFA GRAIL solution was developed to minimize post-procedure complications and ease the concerns patients often face when considering BPH treatment, particularly those involving urinary or sexual function.
Eligibility for the REBOUND Study
The REBOUND Study is for men 45 and older with symptomatic benign prostatic hyperplasia. Study timing and detailed eligibility requirements will be confirmed.